Hepion Pharmaceuticals, Inc. HEPA
Set alert
As of Oct 30, 3:38 PM ET
- YTD
- +200.00%
- 1 year
- +172.73%
- Open
- 0.19
- Prev close
- 0.1478
- Mkt cap
- 22.18M
- Vol
- 31.22K
- Avg vol
- 35.63K
- EPS
- -0.19
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.159
- High
- 0.1999
- Forward P/E
- -0.04
- Beta
- 1.81
- Short ratio
- 0.92
- Inst. own
- 7.85%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 14, 2023
- 50-d avg
- 0.64064
- 200-d avg
- 1.07
- 1y target
- 0.00
Key statistics
- Market cap
- 3.48M
- Enterprise value
- 3.68M
- Trailing P/E
- 0.00
- Forward P/E
- -0.04
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.43
- EPS (TTM)
- -4.40
- Beta
- 1.81
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -26.45M
- Total cash
- 2.12M
- Total debt
- 154.09K
- Return on equity
- -189.51%
- Shares outstanding
- 6.96M
- Short % of float
- 1.13%
- 50-day average
- 0.64064
- 200-day average
- 1.07
Analyst view
Consensus: none
Next earnings
Aug 14, 2023
Expected Aug 14, 2023. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | 0.00 | -0.72 | — | — |
| Aug 13, 2024 | Jun 1, 2024 | 0.00 | -0.68 | — | — |
| May 21, 2024 | Mar 1, 2024 | 0.00 | -0.56 | — | — |
| Apr 16, 2024 | Dec 1, 2023 | 0.00 | -2.42 | — | — |
| Nov 20, 2023 | Sep 1, 2023 | -2.68 | -2.74 | -0.06 | -2.24% |
| Aug 14, 2023 | Jun 1, 2023 | 0.00 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 7, 2023 | Brookline Capital | down | Buy | Hold |
About Hepion Pharmaceuticals, Inc.
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor is in Phase 2b clinical trial to target multiple pathologic pathways involved in the progression of liver disease and treat non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- hepionpharma.com
News
- Hepion Pharmaceuticals Receives Positive FDA Response on GV104 in Gambling Disorder, a Condition With No Approved Medication
- Hepion Pharmaceuticals Completes Acquisition of Gravitas Life Sciences and Provides Corporate Update
- MusclePharm (OTCMKTS:MSLP) & Hepion Pharmaceuticals (NASDAQ:HEPA) Critical Contrast
- Hepion Pharmaceuticals In-Licenses ctRNA Biomarker Assay to Facilitate Early Diagnosis and Surveillance of Hepatocellular Carcinoma
- 12 Health Care Stocks Moving In Thursday's Intraday Session
- 12 Health Care Stocks Moving In Wednesday's Intraday Session
- 12 Health Care Stocks Moving In Friday's Intraday Session
- Hepion Pharmaceuticals Successfully Completes Application to the OTCQB
- 12 Health Care Stocks Moving In Monday's After-Market Session
- Hepion Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq
Your note
Sign in to keep a note on HEPA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| FOSTER ROBERT T PH.D. | Chief Executive Officer | Purchase | Sep 17, 2023 | 50,470 |
| WIJNGAARD PETER | Director | Purchase | Nov 26, 2023 | 9,501 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Anson Funds Management LP | 3.33% | 231,849 | 115.88K | Sep 29, 2024 |
| Vanguard Group Inc | 1.31% | 90,922 | 45.44K | Sep 29, 2024 |
| Blackrock Inc. | 1.19% | 82,954 | 41.46K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.68% | 47,026 | 23.50K | Sep 29, 2024 |
| Citadel Advisors Llc | 0.42% | 29,307 | 14.65K | Sep 29, 2024 |
| Renaissance Technologies, LLC | 0.24% | 16,564 | 8.28K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 0.70% | 48,908 | 24.44K | Sep 29, 2024 |
| Vanguard Total Stock Market Index Fund | 0.58% | 40,671 | 20.33K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.46% | 31,992 | 15.99K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.09% | 6,431 | 3.21K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.08% | 5,269 | 2.63K | Oct 30, 2024 |
| DFA Investment Dimensions-DFA VA U.S. Targeted Value Portfolio | 0.01% | 688 | 343 | Jul 30, 2024 |